Track NexGel Inc Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

NexGel Inc Common Stock NXGL Open NexGel Inc Common Stock in new tab

0.5110 USD
EPS
-0.40
P/B
0.93
ROE
-52.74
Beta
0.74
NexGel Inc Common Stock logo

NexGel Inc Common Stock

🧾 Earnings Recap – Q3 2025

NEXGEL reported stable revenue of $2.9 million in Q3 2025 with improved gross profit margins and a narrowing adjusted EBITDA loss, reflecting operational efficiencies and strong demand in contract manufacturing.

  • Contract manufacturing revenue reached $907,000, supported by strong partnerships, particularly with Cintas for wound care kits.
  • Adjusted EBITDA loss narrowed to $354,000, showing improvement from previous quarters.
  • Consumer brand segment remains stable, with new product launches anticipated to drive sales growth in Q4, including Silly George's lip gloss and Kenco Derm's eczema solutions.
  • Strategic partnership with Stada expanded to include new product launches aimed at the North American market, backed by significant non-dilutive financing.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 11, 2026
EPS-0.40
Book Value0.55
Price to Book0.93
Debt/Equity63.14
% Insiders15.653%
Growth
Revenue Growth-0.08%
Estimates
Forward P/E0.62
Forward EPS0.82

DCF Valuation

Tweak assumptions to recompute fair value for NexGel Inc Common Stock (NXGL)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

NexGel Inc Common Stock Logo NexGel Inc Common Stock Analysis (NXGL)

United States Health Care Official Website Stock

Is NexGel Inc Common Stock a good investment? NexGel Inc Common Stock (NXGL) is currently trading at 0.5110 USD.

Earnings Schedule: NexGel Inc Common Stock is expected to release its next earnings report on Aug. 11, 2026. The market consensus estimate for Forward EPS is 0.82.

Investor FAQ

Does NexGel Inc Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is NexGel Inc Common Stock?

NexGel Inc Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 11, 2026. The company currently has a trailing EPS of -0.40.

Company Profile

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also develops NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. It serves its customers under Medagel, Kenkoderm and Silly George brand names. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was incorporated in 2009 and is based in Langhorne, Pennsylvania.

Exchange Ticker
NMS (United States) NXGL

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion